US-based eyecare technology developer PowerVision has extended its series D round to $40m, according to a regulatory filing on Tuesday, having secured funding from Alcon, an eyecare subsidiary of pharmaceutical firm Novartis.
Founded in 2002, PowerVision is developing an intraocular implant for patients suffering from cataracts and presbyopia, a type of farsightedness associated with old age. The implant is inserted into the eye’s capsular bag during cataract removal surgery and mimics its natural functioning
Alcon made the investment as part…
